Evidence map›Paper›PMID 31168357›Full record

ReviewF1000Research2019

A new look at IgE beyond allergies.

Andrea J Luker, Joseph C Lownik, Daniel H Conrad, Rebecca K Martin

Open access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Eosinophilia and elevated IgE serum levels: a red flag: when your diagnosis is not a common atopic eczema or common allergy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrea J LukerDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA.
Joseph C LownikDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA.
Daniel H ConradDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0002-4791-2694
Rebecca K MartinDepartment of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA.
Virginia Commonwealth University · US

Funding

STRUCTURE/FUNCTION OF THE LYMPHOCYTE FCE RECEPTORR01AI018697 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI MARTIN, REBECCA KELLEY · 1985 to 2018
$6.5M
IL-25 as a master regulator of extrafollicular benign IgER56AI139658 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI MARTIN, REBECCA KELLEY · 2019 to 2019
$380k
NIAID NIH HHS R01 AI018697NIAID NIH HHS R56 AI139658
6 · The paper itself

Abstract

Immunoglobulin E (IgE), though constitutively present at low levels, is most commonly studied in atopic disease where it plays a vital role in mast cell degranulation and in initiating a T helper 2 (Th2) response. With the advent of better detection assays, however, researchers are discovering the importance of IgE in actively contributing to many disease states and pathologies. This review will discuss the latest findings in IgE beyond its role in allergies and recently discovered roles for IgE in its cell-bound form on FcεRI-expressing effector cells like monocytes and dendritic cells. In terms of parasites, we will discuss helminth-induced IgE that appears to protect the worms from immune recognition and a tick-borne illness that elicits an IgE response against red meat. Next, we describe recent findings of how auto-reactive IgE can contribute to the progression of lupus and induce organ damage. Finally, we summarize the emerging roles of IgE in tumor surveillance and antibody-dependent cytotoxicity. We additionally discuss recent or ongoing clinical trials that either target harmful IgE or use the unique characteristics of the isotype.

Indexed as

AnimalsCell DegranulationDendritic CellsHelminthsHumansHypersensitivityImmunoglobulin EMast CellsMonocytesReceptors, IgETh2 CellsImmunoglobulin EReceptors, IgEalpha-galauto-immunitycancerhelminthIgElupustumor

Identifiers

PMID31168357
PMCPMC6537913
OpenAlexW2944910020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.